Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Chae, Young Kwang, Arya, Ayush, Iams, Wade, Cruz, Marcelo R., Chandra, Sunandana, Choi, Jaehyuk, Giles, Francis
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5956851/
https://ncbi.nlm.nih.gov/pubmed/29769148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0349-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars